Lori Sheremeta, LL.M., a lawyer and research officer at the National Research Council's National Institute for Nanotechnology at the University of Alberta, Edmonton, Canada, and special advisor to Alberta InnovatesTechnology Futures, discussed regulatory and public policy challenges regarding nanomaterials in the face of scientific uncertainty.
"One of the most promisingbut also challengingaspects of nanomedicine is that we do not know exactly what the next scientific discovery or breakthrough will bring," said Sheremata. "However, the promise of nanomedicine and molecular imaging is the ability to revolutionize the field and change the way in which many common diseases are diagnosed and treated."
Nanotechnology, Biodistribution and Drug Development
At another session, John V. Frangioni, M.D., Ph.D., associate professor of medicine and radiology, and Hak Soo Choi, Ph.D., instructor in medicine at Harvard Medical School's Beth Israel Deaconess Medical Center, spoke about design considerations for nanoparticles that interact with the body.
"Using quantum dots as a model system, we have systematically defined the physicochemical parameters that mediate uptake of nanoparticles by the lung, their biodistribution to tissues, organs and tumors and their clearance from the body," said Frangioni. "This represents the complete cycle of nanoparticle trafficking from the environment, through the body and back to the environment."
Dr. Frangioni and Dr. Choi's presentations reviewed recent developments in the field and discussed how this new understanding of nanoparticles might guide future studies in air pollution, drug delivery and carcinogenesis.
Using Nanotechnology to Diagnose and Treat Disease
King Li, M.D, M.B.A., chair of the department of radiology at the Methodist Hospital Research Institute, spoke at a third session that gave participants the opportuni
|Contact: Amy Shaw|
Society of Nuclear Medicine